LSB Profile
LakeShore Biopharma Co., Ltd. is a pioneering biopharmaceutical firm dedicated to advancing vaccines and therapeutic biologics. With a strong focus on infectious diseases and cancer treatments, the company's research and development efforts are anchored by its proprietary PIKA immunomodulating technology platform. LakeShore Biopharma is actively engaged in discovering, developing, manufacturing, and commercializing products such as the PIKA rabies vaccine, PIKA recombinant COVID-19 vaccine, and PIKA YS-ON-001, aimed at addressing critical global health challenges.
Headquartered in Beijing, China, LakeShore Biopharma operates on an international scale with presence in key markets including the United States, Singapore, the United Arab Emirates, and the Philippines. Originally established in 2002 as YS Biopharma Co., Ltd., the company rebranded to LakeShore Biopharma Co., Ltd. in May 2024, reflecting its expanded scope and strategic vision in the biopharmaceutical sector.
With a commitment to innovation and global health impact, LakeShore Biopharma continues to expand its portfolio and strengthen its market position. The company's dedication to scientific excellence and rigorous regulatory standards underscores its mission to deliver safe, effective, and accessible healthcare solutions worldwide. Positioned at the forefront of biopharmaceutical innovation, LakeShore Biopharma remains poised for significant growth and contributions to medical advancements in the years ahead.
|
